Brian Culley, Lineage Cell Therapeutics CEO
Roche, Genentech tap regenerative cell therapy player for drug collaboration in eye disease
In a lucrative market for ocular degeneration, Roche has long sat on a gold mine with its drug Lucentis — but the times are changing, and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
